BXRXQ (Baudax Bio) Research & Development: $8.29 Mil (TTM As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BXRXQ Baudax Bio Inc BXRXQ
12 GF Score
Price $0.00
View Full Analysis

What is Baudax Bio Research & Development?

Baudax Bio BXRXQ -99.00% 12 Research & Development is $8.29 Mil as of Sep. 2023. GuruFocus rates BXRXQ with a GF Score™ of 12/100.

Research & Development is the aggregate amount of research and development expenses during the year. Baudax Bio's Research & Development for the three months ended in Sep. 2023 was $1.90 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2023 was $8.29 Mil.

Baudax Bio  (OTCPK:BXRXQ) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Baudax Bio Research & Development Related Terms

Baudax Bio Research & Development Historical Data

* Premium members only.

The historical data trend for Baudax Bio's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Baudax Bio Research & Development Chart

Baudax Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Research & Development
Get a 7-Day Free Trial 35.58 20.06 9.09 3.13 3.89

Baudax Bio Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.62 1.69 2.92 1.78 1.90
BXRXQ
12GF Score
Baudax Bio Inc BXRXQ
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Baudax Bio Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $8.29 Mil mean?
Baudax Bio (BXRXQ) has a Research & Development of $8.29 Mil as of Sep. 2023. Research and development expense is the total cost for research and development activities. View historical data on Baudax Bio and its competitors.
Is Baudax Bio's Research & Development too high?
Baudax Bio's current Research & Development is $8.29 Mil. Overall, Baudax Bio has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Baudax Bio's Research & Development compare to INM and NBRVF?
Baudax Bio's Research & Development of $8.29 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Baudax Bio and its competitors. Baudax Bio's current Research & Development is $8.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Baudax Bio stock overvalued right now?
Baudax Bio (BXRXQ) has a current Research & Development of $8.29 Mil. The current Research & Development is $8.29 Mil. Baudax Bio's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Baudax Bio (BXRXQ), the current Research & Development is $8.29 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Baudax Bio Business Description

Address 490 Lapp Road, Malvern, PA, USA, 19355
Baudax Bio Inc is a Pharmaceutical company. The company develops and commercialize products for hospital and related acute care settings. Its products are in pipeline which includes two novel neuromuscular blocking agents, or NMBAs and a dedicated reversal agent.
12GF Score

Get the complete analysis for BXRXQ

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price